Ashland (ASH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended March 2025, Ashland (ASH) reported revenue of $479 million, down 16.7% over the same period last year. EPS came in at $0.99, compared to $1.27 in the year-ago quarter.The reported revenue represents a surprise of -5.86% over the Zacks Consensus Estimate of $508.82 million. With the consensus EPS estimate being $1.10, the EPS surprise was -10.00%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Life Sciences: $172 million versus $177.02 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -22.5% change. Revenue- Intermediates: $37 million versus $36.38 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change. Revenue- Specialty Additives: $134 million compared to the $141.10 million average estimate based on two analysts. The reported number represents a change of -14.7% year over year. Revenue- Personal Care: $146 million versus the two-analyst average estimate of $162.83 million. The reported number represents a year-over-year change of -13.6%. Adjusted EBITDA- Life Science: $56 million versus $53.75 million estimated by two analysts on average. Adjusted EBITDA- Intermediates: $2 million versus the two-analyst average estimate of $6.15 million. Adjusted EBITDA- Specialty Additives: $26 million compared to the $25.22 million average estimate based on two analysts. Adjusted EBITDA- Personal Care: $44 million versus $46.25 million estimated by two analysts on average. View all Key Company Metrics for Ashland here>>>Shares of Ashland have returned -7.4% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ashland Inc. (ASH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks